已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

威罗菲尼 医学 临床终点 黑色素瘤 内科学 肿瘤科 临床试验 转移性黑色素瘤 癌症 癌症研究
作者
Reinhard Dummer,Paolo A. Ascierto,Helen Gogas,Ana Arance,Mario Mandalà,Gabriella Liszkay,Claus Garbe,Dirk Schadendorf,Ivana Krajsová,Ralf Gutzmer,Vanna Chiarion‐Sileni,Caroline Dutriaux,Jan Willem B. de Groot,Naoya Yamazaki,Carmen Loquai,Laure A Moutouh-de Parseval,Michael D. Pickard,Victor Sandor,Caroline Robert,Keith T. Flaherty
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:19 (5): 603-615 被引量:1004
标识
DOI:10.1016/s1470-2045(18)30142-6
摘要

Combined BRAF-MEK inhibitor therapy is the standard of care for BRAFV600-mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafenib in patients with advanced BRAFV600-mutant melanoma.COLUMBUS was conducted as a two-part, randomised, open-label phase 3 study at 162 hospitals in 28 countries. Eligible patients were aged 18 years or older and had histologically confirmed locally advanced (American Joint Committee on Cancer [AJCC] stage IIIB, IIIC, or IV), unresectable or metastatic cutaneous melanoma, or unknown primary melanoma; a BRAFV600E or BRAFV600K mutation; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; and were treatment naive or had progressed on or after previous first-line immunotherapy. In part 1 of the study, patients were randomly assigned (1:1:1) via interactive response technology to receive either oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily (encorafenib plus binimetinib group), oral encorafenib 300 mg once daily (encorafenib group), or oral vemurafenib 960 mg twice daily (vemurafenib group). The primary endpoint was progression-free survival by blinded independent central review for encorafenib plus binimetinib versus vemurafenib. Efficacy analyses were by intention-to-treat. Safety was analysed in patients who received at least one dose of study drug and one postbaseline safety assessment. The results of part 2 will be published separately. This study is registered with ClinicalTrials.gov, number NCT01909453, and EudraCT, number 2013-001176-38.Between Dec 30, 2013, and April 10, 2015, 577 of 1345 screened patients were randomly assigned to either the encorafenib plus binimetinib group (n=192), the encorafenib group (n=194), or the vemurafenib group (n=191). With a median follow-up of 16·6 months (95% CI 14·8-16·9), median progression-free survival was 14·9 months (95% CI 11·0-18·5) in the encorafenib plus binimetinib group and 7·3 months (5·6-8·2) in the vemurafenib group (hazard ratio [HR] 0·54, 95% CI 0·41-0·71; two-sided p<0·0001). The most common grade 3-4 adverse events seen in more than 5% of patients in the encorafenib plus binimetinib group were increased γ-glutamyltransferase (18 [9%] of 192 patients), increased creatine phosphokinase (13 [7%]), and hypertension (11 [6%]); in the encorafenib group they were palmoplantar erythrodysaesthesia syndrome (26 [14%] of 192 patients), myalgia (19 [10%]), and arthralgia (18 [9%]); and in the vemurafenib group it was arthralgia (11 [6%] of 186 patients). There were no treatment-related deaths except for one death in the combination group, which was considered possibly related to treatment by the investigator.Encorafenib plus binimetinib and encorafenib monotherapy showed favourable efficacy compared with vemurafenib. Overall, encorafenib plus binimetinib appears to have an improved tolerability profile compared with encorafenib or vemurafenib. Encorafenib plus binimetinib could represent a new treatment option for patients with BRAF-mutant melanoma.Array BioPharma, Novartis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zuofighting发布了新的文献求助10
刚刚
瘦瘦苑博完成签到,获得积分10
刚刚
insomnia417完成签到,获得积分0
刚刚
lzl008完成签到 ,获得积分0
1秒前
领导范儿的应助被邢绿凝采纳,获得10
1秒前
稚祎完成签到 ,获得积分0
2秒前
3秒前
俏皮含双完成签到,获得积分10
4秒前
Eina发布了新的文献求助10
4秒前
枫落完成签到 ,获得积分10
4秒前
吴建军完成签到,获得积分10
4秒前
善良的嫣完成签到,获得积分10
5秒前
Qiiii完成签到,获得积分10
5秒前
淙淙完成签到,获得积分10
5秒前
明白放弃完成签到,获得积分10
5秒前
星星完成签到 ,获得积分10
5秒前
爱听歌的代曼完成签到 ,获得积分10
6秒前
凌儿响叮当完成签到 ,获得积分10
6秒前
呆萌井完成签到,获得积分10
7秒前
VERY完成签到,获得积分10
8秒前
cheqi完成签到 ,获得积分10
9秒前
9秒前
荔枝完成签到 ,获得积分10
9秒前
jinjinjin完成签到 ,获得积分10
9秒前
查不到我就吃饭完成签到 ,获得积分10
9秒前
故然完成签到 ,获得积分10
10秒前
hanhan完成签到 ,获得积分10
10秒前
lzl007完成签到 ,获得积分0
10秒前
谎1028完成签到 ,获得积分10
12秒前
爆米花糖完成签到 ,获得积分10
13秒前
13秒前
所所的应助被bibai28采纳,获得20
13秒前
WUXICG完成签到 ,获得积分10
14秒前
Lan完成签到 ,获得积分10
16秒前
淡定又夏完成签到 ,获得积分10
16秒前
泡泡糖完成签到,获得积分10
16秒前
16秒前
马达发布了新的文献求助10
17秒前
safeandsound完成签到 ,获得积分10
17秒前
清浔完成签到 ,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189866
求助须知:如何正确求助?哪些是违规求助? 9577019
关于积分的说明 21851254
捐赠科研通 7787798
什么是DOI,文献DOI怎么找? 3435795
关于科研通互助平台的介绍 2559856
邀请新用户注册赠送积分活动 2482699